Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129770 | 0.86 | KMT2A (0.50) | KMT2APOLBLMNAMEN1ALDH1A1 | |
| SCHEMBL148633 | 0.86 | KMT2A (0.58) | KMT2APOLBLMNAMEN1L3MBTL1 | |
| SCHEMBL192786 | 0.85 | LMNA (0.61) | KMT2APOLBLMNAMEN1ALDH1A1 | |
| SCHEMBL129021 | 0.81 | KMT2A (0.50) | KMT2APOLBLMNAMEN1ALDH1A1 | |
| SCHEMBL129809 | 0.80 | KMT2A (0.53) | KMT2APOLBMEN1ALDH1A1KDM4E | |
| SCHEMBL129828 | 0.78 | KMT2A (0.51) | KMT2APOLBLMNAMEN1ALDH1A1 | |
| SCHEMBL6381209 | 0.76 | CA1 (0.61) | KMT2APOLBLMNAMEN1L3MBTL1 | |
| SCHEMBL9988696 | 0.76 | MTNR1A (0.54) | — | |
| SCHEMBL17212230 | 0.76 | CA1 (0.60) | KMT2APOLBLMNAMEN1ALDH1A1 | |
| SCHEMBL6382633 | 0.75 | CA1 (0.69) | KMT2APOLBMEN1L3MBTL1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227966-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140315939-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-10-23 | — | — | US | disclosed |
| US-20120059026-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059026-A1 | ANTIMICROBIAL AGENTS | ZYX, Q6ZSR9, ZC3HAV1L | KMT2A 2296/4885POLB 2698/4885LMNA 3821/4885 |
| US-20140315939-A1 | ANTIMICROBIAL AGENTS | ZYX, Q6ZSR9, ZC3HAV1L | KMT2A 2237/4885POLB 3196/4885LMNA 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.